Motor improvements in SMA adults treated with Spinraza paralleled a boost in electrical impulses along nerves that supply ...

Liver damage related to Zolgensma gene therapy usually resolves within a few months of treatment, a study found.

Ionis Pharmaceuticals beat Q1 earnings and revenue estimates, raising its 2025 outlook, and reported strong sales from new ...

The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted Biogen’s applications for a higher dose regimen of spinal muscular atrophy (SMA) treatment Spinraza ...

Spinal muscular atrophy (SMA) treatment has evolved significantly ... onasemnogene abeparvovec-xioi (Zolgensma), nusinersen (Spinraza), and risdiplam (Evrysdi). She highlights the unique ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the first quarter ended March ...

approved the first treatment for spinal muscular atrophy (SMA), a devastating neurodegenerative disorder and the leading genetic cause of death in infants. A clinical trial earlier this year ...

The cost of Spinraza injection can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Spinraza.

With a market cap of $17.4 billion, Biogen Inc. (BIIB) is a global biotechnology leader focused on discovering, developing, ...

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. First quarter of ...

Biogen's treatment for neurodegenerative disorder spinal muscular atrophy (SMA) Spinraza has come under pressure in an increasingly competitive market, but the company hopes a new high-dose ...